Schedule Demo

Transpara® Breast AI at RSNA 2025

Booth #4719

Nov 30-Dec 4, 2025

McCormick Place, Chicago, USA

Schedule a demo

We are excited to announce our participation in the Radiological Society of North America (RSNA) Annual Meeting, taking place from November 30-December 4, 2025, in Chicago, Illinois.

Book a 15-minute demo today to secure your dedicated time with our experts during RSNA 2025 and get all your questions answered in person.
 
See you in Chicago and meet The Breast AI company trusted by radiologists worldwide.
Clinical chats Program Schedule a demo Booth

Location

We're located in Booth #4719, South Hall 

Sunday, Nov 30 10:00 AM - 5:00 PM CT
Monday, Dec 1 10:00 AM - 5:00 PM CT
Tuesday, Dec 2 10:00 AM – 5:00 PM CT
Wednesday, Dec 3  10:00 AM - 5:00 PM CT

Venue

McCormick Place 

2301 S Martin Luther King Dr.

Chicago, Illinois 60616

See Transpara®

in action and read real-life cases with our co-founder Prof. Nico Karssemeijer, the most cited researcher in Breast AI.
See Transpara®

Meet the team

of dedicated experts and clinical specialists and get all your questions answered.
Meet the team

Discover the Transpara® Breast AI Suite

Transpara® Detection, Density and Temporal Comparison to support your workflow and diagnostics.
Discover the Transpara® Breast AI Suite

Clinical Chats

Renowed figures in breast imaging, Prof. PhD Nico Karssemeijer, Dr. Rachel Brem and Dr. Roger Yang, will be joining us at RSNA as part of our Clinical Chats Series at the ScreenPoint Medical Booth 4719, South Hall.

These sessions will provide an exclusive opportunity to hear firsthand how Transpara Breast AI is shaping clinical practice, improving efficiency and supporting earlier detection in real-world environments.

8

Prof. PhD Nico Karssemeijer

Co-Founder and Chief Scientific Officer, ScreenPoint Medical, Professor Emeritus at Radboud University, Nijmegen.

ScreenPoint Medical's co-founder discusses advances in the field of Breast AI and what the future holds.

Sunday, November 30, 1:00-2:00 PM CT

Add to your calendar

6

Dr. Rachel Brem, MD, FACR, FSBI

Director of Breast Imaging & Intervention, George Washington University Hospital. Co-Author, No Longer Radical

Dr. Brem will discuss innovation in action and how she and her organization are caring for their population more effectively through AI.

Monday, December 1, 1:00-2:00 PM CT

Add to your calendar

7

Dr. Roger Yang, MD, FACR

President, University Radiology Group and Clinical Associate Professor of Radiology, Rutgers University

Dr. Yang will discuss the ROI of Breast AI and how leaders can manage and adapt to change and transformation across the industry.

Tuesday, December 2, 1:45-2:45 PM CT

Add to your calendar

Scientific Sessions with ScreenPoint Medical

S5-SSBR02. Breast Imaging (Breast Cancer Risk Prediction)

S5-SSBR02-4. Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-year Time Period with Mammography

Speaker: MSc. Yao-Kuan Wang, KU Leuven
Date and time: 11/30/2025, 2:30 PM      
Location: S406A

For the detection regime, Transpara Detection and Risk outperformed RSNA CAD and Mirai, with AUCs of 0.92 (0.91-0.93) and 0.92 (0.91-0.93) vs. 0.90 (0.88-0.91) and 0.86 (0.84-0.87), all p < 0.001. For the risk regime, Transpara Risk demonstrated the best performance, with an AUC of 0.81 (0.79-0.84), all p < 0.001.

After setting operating points, in the detection regime, Transpara Detection achieved the lowest false positive rates (FPR) of 2.84%, similar to 3% in European screening. Detection models excelled in screen-detected cancers, while risk models performed better for interval cancers.

T3-SSBR05. Breast Imaging (Screening Mammography Workflow and AI Applications)

T3-SSBR05-4. Diagnostic Performance of Screening Mammography AI Tool in a Cancer Center Screening Population

Speaker: PhD. Sarah Eskreis-Winkler, Memorial Sloan Kettering Cancer Center
Date and time: 12/2/2025, 9:30 AM                                    
Location: S406A

AI algorithms may perform less effectively in real world settings compared to results reported in the literature, particularly at imaging centers with high volumes of patients with history of breast conserving therapy.

 

T3-SSBR05-6. Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis in a Dutch Population-based Screening Cohort

Speaker: MSc. Sarah D. Verboom, Radboud UMC
Date and time: 12/2/2025, 9:30 AM              
Location: S406A

There are significant differences in performance between some of the four commercial AI algorithms when evaluating screening DBT examinations.Transpara had the most accurate performance: AUC: 0.978 (95%CI 0.967-0.989)

 

T3-SSBRO5-6. Use of Multiple Prior Exams Improves Specificity of an AI System for Breast Cancer Detection in a Retrospective Multi-site Validation

Speaker: PhD. Nico Karssemeijer, ScreenPoint Medical
Date and time: 12/2/2025, 9:30 AM                                
Location: S406A

An AI system for breast cancer detection in tomosynthesis achieves a higher specificity when using prior exams for analysis. Results were not affected by breast density and the benefit of priors may be higher when multiple priors are used.

W5B-SPBR. Breast Imaging Wednesday Afternoon Poster Discussions II

W5B-SPBR-3. Real-World Performance of an FDA-approved Artificial Intelligence Tool for Screening Mammography 

Speaker: MD. MS. Emily Ambinder, Johns Hopkins
Date and time: 12/3/2025, 12:45 PM   
Location: Learning Center

The AI algorithm showed appropriate risk stratification corresponding to cancer detection rates of 0.5, 8.4, and 98 in the three risk categories. AI had improved performance in dense breast tissue with a higher percentage of exams in dense breasts assessed as low risk compared to exams in non dense breasts without significantly impacting cancer detection rate.

R1-SSBR10. Breast Imaging (Digital Breast Tomosynthesis)

AI Pre-reading of Digital Breast Tomosynthesis: A Multi-site Validation of a Novel Imaging Biomarker for Confident Identification of Normal DBT Examinations

Speaker: MSc. Joep Stevens, ScreenPoint Medical
Date and time: 12/4/2025, 8:00 AM  
Location: S406A

A novel AI-driven imaging biomarker for pre-reading of DBT can confidently identify approximately one‑third of normal DBT examinations in breast cancer screening with a negative predictive value nearing 100%.

 

Reserve your personal demo at RSNA 2025

See Transpara® for breast cancer screening in action during a personal demo. One of our experts will walk you through how Transpara® supports radiologists with faster, more accurate detection and answer all your questions.

Please enter your details in the form below so we can confirm your demo and prepare it for your needs. Once submitted, you'll be redirected to choose the time that works best for you.

 

Dana Ahrold RSNA 2025

Dana Ahrold

Sales Director, West Region USA

Dana Ahrold
4

Jen Skanron

Sales Director, Central Region USA

Jen Skanron
Kerri Waldren RSNA 2025

Kerri Waldren

Sales Director, Great Lakes + Canada

Kerri Waldren
Lisa Bolton 2025

Lisa Bolton

Sales Director, East Region USA

Lisa Bolton

Transpara® at Booth #4719, South Hall 

RSNA 2025 Booth
Schedule Demo